Pharma

Your Article Summary

See Latest Articles

Approval of a New Indication for Oxarol Ointment/Lotion (nonproprietary name: maxacalcitol), Psoriasis Vulgaris Treatment Topical Products Containing Active Vitamin D3, for Extended Treatment of Palmoplantar Pustulosis
Chugai Pharmaceutical Co., 01/23/09

Maruho Co., Ltd. [Head Office, Kita-ku, Osaka; President, Koichi Takagi] (hereafter, "Maruho") and Chugai Pharmaceutical Co., Ltd. [Head Office, Chuo-ku, Tokyo; President, Osamu Nagayama] (hereafter, "Chugai") are pleased to announce that the Ministry of Health, Labour and Welfare approved a new indication for Oxarol Ointment 25mcg/g (hereafter, "Ointment") and Oxarol Lotion 25mcg/g (hereafter, "Lotion"), treatment drugs for keratosis including psoriasis vulgaris, for extended treatment of palmoplantar pustulosis. Chugai has the marketing approval and Maruho distributes for the products.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

See All of Drug/Product Approvals